Astrazeneca Ab

Erik Söderlind

Anette Larsson

Karl Hult

Christian Von Corswant

Hans Carlsson

Fredrik Viklund

Karl Kungliga Tekniska Högskolan Hult

New non-ionic surfactants in the form of polyoxyalkylene glycol hydroxy fatty acid derivatives or monoalkylated polyoxyalkylene glycol hydroxy fatty acid derivatives having a polyoxyalkylene/alkyl polyoxyalkylene chain with a chain-length of 25-455 repeating units and a specified substituent on the hydroxy position of the specified hydroxy fatty acid, according to the general formula (I) CH&#x2014;(CH)&#x2014;CH&#x2014;(CH)&#x2014;CO&#x2014;[&#x2014;O&#x2014;R&#x2014;]&#x2014;O&#x2014;RR&#x2014;O (I); wherein for example Ris methyl, Ris optionally substituted C-Cacyl, alkyl, or alkenyl, Ris ethylene, x is 2-12, y is 7-17, (x+y) is 3-19 and z is 25-57; advantageously prepared by involving an enzymatic process, formulations comprising them, their use as solubilizers and a process involving a hydrolytic enzyme for preparing them. 

Non-ionic surfactants for poorly soluble molecules

The present invention concerns polymer particle vaccine delivery systems in which a water insoluble protein antigen, e.g. a lipidated HpaA protein, is incorporated with particles comprising a polymer matrix. The present invention also concerns a method for incorporating such a water insoluble protein antigen with a polymer matrix in order to produce a polymer particle vaccine delivery system. In addition, the invention also provides a vaccine composition comprising the polymer particle delivery system. The vaccine can be used to treat and/or reduce the risk of for example Helicobacter infection.

Antigen delivery system and method of production

Growing community of inventors

Mölndal, Sweden

Erik Söderlind